Exclusive Interview: Dr. William A. Carter, CEO. Hemispherx Biopharma, Inc. (AMEX:HEB) |
 |
 |
| By M.E.Garza |
| Friday, 12 June 2009 20:48 |
|
Warning: Due To Heavy Traffic And Length, The Screen May Not Load For A Few Seconds. Please Be Patient.
TRT: Approximately 45 Minutes BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section Add this page to your favorite Social Bookmarking websites            |
Dr.William A. Carter, the CEO of Hemispherx Biopharma shares his thoughts on the FDA delay, the flu pandemic and the future of his company. Late in the interview he also answers questions submitted to us by our readers. Certainly, the interview is filled with candid revelations and interesting nuggets of new information.
about 4 hours ago
Medtronic Receives Notification of Activities Relating to INFUSE Bone Graft; FDA Receives Repros' Submission And... http://t.co/vTjySscD
about 17 hours ago
OraSure In-Home HIV Test Kit Moves Closer to FDA Approval http://t.co/3apZYJHb
about 17 hours ago
USA boosts Alzheimer's funding as prevention trial is launched: http://t.co/6HGiQuIu
about 17 hours ago
How payers, pharmas are experimenting with outcomes based reimbursement http://t.co/aV10VjPJ
about 18 hours ago
Will Mayo v. Prometheus Fire Up Pharma?: Kevin DeGeeter: Newly discovered biomarkers could provide physicians wi... http://t.co/doXumsu8
about 23 hours ago
Sugar makes you stupid: Study shows high-fructose diet sabotages learning, memory http://t.co/TuGuFq1F
about 23 hours ago
'Fat tax' - http://t.co/8M5qcfp0
about 23 hours ago
Nice approves prostate cancer drug - Health News - Health & Families - The Independent http://t.co/A8HSYzEd
Free Phone Trade Alerts
